Effects of intense pulsed light treatment on tear cytokines and clinical outcomes in meibomian gland dysfunction

Qian Li, Junxiu Liu, Cheng Liu, Junfeng Piao, Wei Yang, Ningyu An, Jinyan Zhu, Qian Li, Junxiu Liu, Cheng Liu, Junfeng Piao, Wei Yang, Ningyu An, Jinyan Zhu

Abstract

Meibomian gland dysfunction (MGD) has become a prevalent ocular surface disorder. Its pathogenesis is regarded as a self-perpetuating inflammatory vicious circle. Intense Pulsed Light (IPL) treatment was recently applied to improve the meibomian gland function and reduce symptoms of MGD. However, studies investigating the change of specific inflammatory cytokines during IPL treatment remained sparse. To further figure out how IPL treatment modulates the inflammatory cytokines in tears of MGD, we therefore performed a cross-sectional study and enrolled 32 patients from March 2019 to December 2020. The patients received 3 sessions of IPL treatment (10 to 16 J/cm2) at 4-week interval. The signs and symptoms of MGD were evaluated by ocular surface disease index (OSDI), tear film breakup time (TBUT), and meibomian gland yield secretion score (MGYSS). The clinical evaluators and tear samples were analyzed at baseline and at each IPL treatment session. Concentrations of (chemokine ligand) CXCL1, (C-C motif chemokine) CCL11, (tumor necrosis factor) TNF-α, (interferon) IFN-γ, (interleukin) IL-2, IL-6 and (tissue inhibitor of metalloproteinase) TIMP-1were measured by Quantibody Human Dry Eye Disease Array1. OSDI significantly decreased after IPL treatment compared with baseline. TBUT and MGYSS increased consecutively during treatment. CXCL1, CCL11, TNF-α, IFN-γ, IL-2, IL-6 presented significantly decrease and TIMP-1 showed significantly increase from the pretreatment baseline. The changed concentrations of TNF-α, IFN-γ, IL-2, TIMP-1 correlated with TBUT, the changed values of CXCL1, TNF-α, IFN-γ, CCL11, IL-2, IL-6, TIMP-1 correlated with MGYSS, and the changed concentrations of CXCL1, IFN-γ, CCL11, IL-2, IL-6 correlated with TIMP-1. The data supported IPL treatment could significantly relieve both signs and symptoms of MGD. The therapeutic effect of IPL treatment may originate from regulation of inflammatory cytokines including CXCL1, TNF-α, IFN-γ, CCL11, IL-2, IL-6, and TIMP-1.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Change of clinical evaluators following…
Fig 1. Change of clinical evaluators following each IPL treatment session in patients with MGD.
(A) TBUT, (B) MGYSS, (C) OSDI. *P<0.05, ***P<0.001.
Fig 2. Change in tear cytokines following…
Fig 2. Change in tear cytokines following each IPL treatment session as a ratio compared with the pretreatment baseline.
(A) CXCL1, (B) TNF-α, (C) IFN-γ, (D) CCL11, (E) IL-2, (F) IL-6, (G) TIMP-1. *P<0.05, ***P<0.001.

References

    1. Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al.. TFOS DEWS II Introduction. The Ocular Surface. 2017;15(3):269–75. doi: 10.1016/j.jtos.2017.05.005
    1. Uchino M, Uchino Y, Dogru M, Kawashima M, Yokoi N, Komuro A, et al.. Dry Eye Disease and Work Productivity Loss in Visual Display Users: The Osaka Study. AM J OPHTHALMOL. 2014;157(2):294–300. doi: 10.1016/j.ajo.2013.10.014
    1. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology of, and Associated Risk Factors for, MGD. Investigative Opthalmology & Visual Science. 2011. 2011-03-30;52(4):1994.
    1. Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, et al.. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. BRIT J OPHTHALMOL. 2016. 2016-01-01;100(3):300–6. doi: 10.1136/bjophthalmol-2015-307415
    1. Thode AR, Latkany RA. Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD). DRUGS. 2015;75(11):1177–85. doi: 10.1007/s40265-015-0432-8
    1. Lienert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. Long-term Natural History of Dry Eye Disease from the Patient’s Perspective. OPHTHALMOLOGY. 2016;123(2):425–33. doi: 10.1016/j.ophtha.2015.10.011
    1. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al.. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Investigative Opthalmology & Visual Science. 2011. 2011-03-30;52(4):1922.
    1. Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. The Ocular Surface. 2019;17(1):104–10. doi: 10.1016/j.jtos.2018.11.004
    1. Multicenter Study of Intense Pulsed Light Therapy for Patients With Refractory Meibomian Gland Dysfunction.
    1. Yin Y, Liu N, Gong L, Song N. Changes in the Meibomian Gland After Exposure to Intense Pulsed Light in Meibomian Gland Dysfunction (MGD) Patients. CURR EYE RES. 2018. 2018-01-01;43(3):308–13. doi: 10.1080/02713683.2017.1406525
    1. Rong B, Tang Y, Liu R, Tu P, Qiao J, Song W, et al.. Long-Term Effects of Intense Pulsed Light Combined with Meibomian Gland Expression in the Treatment of Meibomian Gland Dysfunction. PHOTOMED LASER SURG. 2018;36(10):562–7. doi: 10.1089/pho.2018.4499
    1. de Godoy CHL, Silva PFDC, de Araujo DS, Motta LJ, Biasotto-Gonzalez DA, Politti F, et al.. Evaluation of effect of low-level laser therapy on adolescents with temporomandibular disorder: study protocol for a randomized controlled trial. TRIALS. 2013. 2013-01-01;14(1):229. doi: 10.1186/1745-6215-14-229
    1. Piccolo D, Di Marcantonio D, Crisman G, Cannarozzo G, Sannino M, Chiricozzi A, et al.. Unconventional Use of Intense Pulsed Light. BIOMED RES INT. 2014;2014:1–10. doi: 10.1155/2014/618206
    1. Borchman D, Foulks GN, Yappert MC, Bell J, Wells E, Neravetla S, et al.. Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction. INVEST OPHTH VIS SCI. 2011. 2011-01-01;52(6):3805–17. doi: 10.1167/iovs.10-6514
    1. Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. OCUL SURF. 2019;2(17). doi: 10.1016/j.jtos.2019.02.005
    1. Farrell HP, Garvey M, Cormican M, Laffey JG, Rowan NJ. Investigation of critical inter-related factors affecting the efficacy of pulsed light for inactivating clinically relevant bacterial pathogens. J APPL MICROBIOL. [Journal Article; Research Support, Non-U.S. Gov’t]. 2010. 2010-05-01;108(5):1494–508. doi: 10.1111/j.1365-2672.2009.04545.x
    1. Ruixing Liu BRPT. Analysis of Cytokine levels in tears and Clinical Correlations after Intense Pulsed. AM J OPHTHALMOL. 2017;183(Nov):81–90. doi: 10.1016/j.ajo.2017.08.021
    1. Choi M, Han SJ, Ji YW, Choi YJ, Jun I, Alotaibi MH, et al.. Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines. SCI REP-UK. 2019;9(1). doi: 10.1038/s41598-019-44000-0
    1. Arita R, Itoh K, Maeda S, Maeda K, Furuta A, Fukuoka S, et al.. Proposed Diagnostic Criteria for Obstructive Meibomian Gland Dysfunction. OPHTHALMOLOGY. 2009;116(11):2058–63. doi: 10.1016/j.ophtha.2009.04.037
    1. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al.. The International Workshop on Meibomian Gland Dysfunction: Report of the Diagnosis Subcommittee. Investigative Opthalmology & Visual Science. 2011. 2011-03-30;52(4):2006.
    1. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. [Journal Article]. 1988. 1988-06-01;124(6):869–71. doi: 10.1001/archderm.124.6.869
    1. BRON AJ, BENJAMIN L, SNIBSON GR. Meibomian gland disease. Classification and grading of lid changes. Eye (London). 1991. 1991-01-01;5(4):395–411. doi: 10.1038/eye.1991.65
    1. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci. [Comparative Study; Journal Article; Research Support, Non-U.S. Gov’t; Research Support, U.S. Gov’t, P.H.S.]. 2002. 2002-04-01;43(4):1004–11.
    1. Albietz JM, Schmid KL. Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. CLIN EXP OPTOM. 2018. 2018-01-01;101(1):23–33. doi: 10.1111/cxo.12541
    1. Vegunta S, Patel D, Shen JF. Combination Therapy of Intense Pulsed Light Therapy and Meibomian Gland Expression (IPL/MGX) Can Improve Dry Eye Symptoms and Meibomian Gland Function in Patients With Refractory Dry Eye: A Retrospective Analysis. CORNEA. [Journal Article]. 2016. 2016-03-01;35(3):318–22. doi: 10.1097/ICO.0000000000000735
    1. Dell SJ. Intense pulsed light for evaporative dry eye disease. 2017; Volume 11:1167–73.
    1. De Filippo K, Henderson RB, Laschinger M, Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J IMMUNOL. [Comparative Study; Journal Article; Research Support, Non-U.S. Gov’t]. 2008. 2008-03-15;180(6):4308–15. doi: 10.4049/jimmunol.180.6.4308
    1. Rangel L. Silva AHLR, Cunha TM. CXCL1_CXCR2 signaling in pathological pain_ Role in peripheral and central sensitization. NEUROBIOL DIS. 2017;105(Sep):109–16. doi: 10.1016/j.nbd.2017.06.001
    1. E A Garcia-Zepeda MERR. © 1996 Nature Publishing Group . Nature Medcine. 1996;4(2):449–56.
    1. Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, et al.. Distinct profiles of Sjögren’s syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. CLIN IMMUNOL. 2005;117(2):168–76. doi: 10.1016/j.clim.2005.06.016
    1. Nocturne G, Seror R, Fogel O, Belkhir R, Boudaoud S, Saraux A, et al.. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren’s Syndrome. ARTHRITIS RHEUMATOL. 2015;67(12):3226–33. doi: 10.1002/art.39315
    1. Cunha TM, Verri WJ, Silva JS, Poole S, Cunha FQ, Ferreira SH. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci U S A. [Comparative Study; Journal Article; Research Support, Non-U.S. Gov’t]. 2005. 2005-02-01;102(5):1755–60. doi: 10.1073/pnas.0409225102
    1. Manjavachi MN, Costa R, Quintão NL, Calixto JB. The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice. NEUROPHARMACOLOGY. 2014;79:17–27. doi: 10.1016/j.neuropharm.2013.10.026
    1. Lee H, Chung B, Kim KS, Seo KY, Choi BJ, Kim T. Effects of Topical Loteprednol Etabonate on Tear Cytokines and Clinical Outcomes in Moderate and Severe Meibomian Gland Dysfunction: Randomized Clinical Trial. AM J OPHTHALMOL. 2014;158(6):1172–83. doi: 10.1016/j.ajo.2014.08.015
    1. Jackson DC, Zeng W, Wong CY, Mifsud EJ, Williamson NA, Ang C, et al.. Tear Interferon-Gamma as a Biomarker for Evaporative Dry Eye Disease. INVEST OPHTH VIS SCI. 2016. 2016-01-01;57(11):4824–30. doi: 10.1167/iovs.16-19757
    1. Benitez-del-Castillo Sánchez J, Morillo-Rojas MD, Galbis-Estrada C, Pinazo-Duran MD. Determinación de mediadores de la respuesta inmune e inflamación en lágrimas: cambios en ojo seco y glaucoma frente a población sana. Archivos de la Sociedad Española de Oftalmología. 2017;92(5):210–7.
    1. Ribelles A, Galbis-Estrada C, Parras MA, Vivar-Llopis B, Marco-Ramírez C, Diaz-Llopis M. Ocular Surface and Tear Film Changes in Older Women Working with Computers. BIOMED RES INT. 2015;2015:1–10. doi: 10.1155/2015/467039
    1. Lee SY, Han SJ, Nam SM, Yoon SC, Ahn JM, Kim T, et al.. Analysis of Tear Cytokines and Clinical Correlations in Sjögren Syndrome Dry Eye Patients and Non–Sjögren Syndrome Dry Eye Patients. AM J OPHTHALMOL. 2013;156(2):247–53. doi: 10.1016/j.ajo.2013.04.003
    1. Jung JW, Han SJ, Nam SM, Kim T, Kim EK, Seo KY. Meibomian gland dysfunction and tear cytokines after cataract surgery according to preoperative meibomian gland status. Clinical & Experimental Ophthalmology. 2016;44(7):555–62. doi: 10.1111/ceo.12744
    1. Baudouin C, Irkeç M, Messmer EM, Benítez-del-Castillo JM, Bonini S, Figueiredo FC, et al.. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. ACTA OPHTHALMOL. 2018;96(2):111–9. doi: 10.1111/aos.13436
    1. Pflugfelder SC, De Paiva CS, Moore QL, Volpe EA, Li DQ, Gumus K, et al.. Aqueous Tear Deficiency Increases Conjunctival Interferon-gamma (IFN-gamma) Expression and Goblet Cell Loss. Invest Ophthalmol Vis Sci. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t]. 2015. 2015-11-01;56(12):7545–50. doi: 10.1167/iovs.15-17627
    1. Pflugfelder SC, de Paiva CS. The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research. Ophthalmology (Rochester, Minn.). 2017. 2017-01-01;124(11S):S4–13. doi: 10.1016/j.ophtha.2017.07.010
    1. Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of Inflammatory Cytokines in the Tears of Dry Eye Patients. CORNEA. 2009. 2009-01-01;28(9):1023–7. doi: 10.1097/ICO.0b013e3181a16578
    1. Kimura K, Morita Y, Orita T, Haruta J, Takeji Y, Sonoda K. Protection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipide. INVEST OPHTH VIS SCI. 2013. 2013-01-01;54(4):2572–760.
    1. Sang-Yun Lee JJTH. Ocotillol, a Majonoside R2 Metabolite, Ameliorates 2,4,6-Trinitrobenzenesulfonic Acid-Induced Colitis in Mice by Restoring the Balance of Th17_Treg Cells. J Agric Food Chem. 2015;31(63):7024–31. doi: 10.1021/acs.jafc.5b02183
    1. Cuerda-Galindo E, Díaz-Gil G, Palomar-Gallego MA, Linares-GarcíaValdecasas R. Increased fibroblast proliferation and activity after applying intense pulsed light 800–1200nm. Annals of Anatomy—Anatomischer Anzeiger. 2015;198:66–72.
    1. Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of extracellular matrix proteolysis. MATRIX BIOL. 2015. 2015-01-01;44–46:247–54. doi: 10.1016/j.matbio.2015.03.005
    1. Jamerson EC, Elhusseiny AM, ElSheikh RH, Eleiwa TK, El Sayed YM. Role of Matrix Metalloproteinase 9 in Ocular Surface Disorders. Eye & Contact Lens: Science & Clinical Practice. 2020;46(2):S57–63. doi: 10.1097/ICL.0000000000000668
    1. Asatsuma M, Ito S, Watanabe M, Takeishi H, Nomura S, Wada Y, et al.. Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjögren’s syndrome. CLIN CHIM ACTA. 2004;345(1–2):99–104. doi: 10.1016/j.cccn.2004.03.006

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe